Market Minds Advisory
Companion Diagnostics Market

Companion Diagnostics Market: Biomarker Concordance Over Menu Breadth

Pharmaceutical sponsors are shifting diagnostic co-development spend from raw test menu breadth toward validated biomarker concordance evidence, as liquid biopsy platforms compete directly against conventional tissue-based testing across major oncology markets worldwide.

Lead Analyst

Alice Ballenger

Published

September 2026

Make Smarter Decisions with Customized Research Insights

Request a free sample report and evaluate market opportunities, growth trends, and competitive dynamics relevant to your business needs.

2025 MARKET VALUE$9.2BMarket Size 2025
2036 FORECAST VALUE$28.4BBase Case , 2026 to 2036
CAGR 2026 TO 203610.8 %Bull 12.1% / Bear 9.5%
INCREMENTAL OPPORTUNITY$18.2BNet 10- year value creation
EXPANSION MULTIPLE2.79x2036 value over 2026 base
Strategic Levers
M&A Pipeline
Regional Outlook
Country Rankings
Competitive Intelligence
Segmental Deep-dive
Call-Us : 91 93563 13602

Executive Snapshot and Market Trajectory

Companion diagnostic selection increasingly turns on validated biomarker concordance data rather than raw test menu breadth alone, as oncologists and pharmaceutical sponsors weigh treatment matching accuracy evidence over simple assay availability broadly across most precision oncology categories entirely and consistently and reliably.
The market stands at USD 10.19 billion in 2025 and reaches USD 28.42 billion by 2036 at a 10.8% CAGR. Liquid biopsy companion diagnostics grow fastest at 16.0%, roughly 1.48 times the overall rate, as oncologists pursue minimally invasive biomarker testing beyond conventional tissue biopsy across categories. North America holds 39% of value on concentrated precision oncology R&D and FDA co-approval pathway dominance, while South Asia and Pacific posts the quickest regional growth at 13.0%.
Concentration sits near 44%, split between diversified diagnostics majors holding broad pharmaceutical partnership distribution and specialty biomarker developers competing on concordance depth and material engineering across most targeted therapy categories worldwide today entirely and consistently now and quite reliably. Two forces dominate ahead. Precision oncology drug approvals are pulling pharmaceutical sponsors toward validated diagnostic co-development, and liquid biopsy adoption is turning minimally invasive testing into a genuine growth driver.
Market Definition
The companion diagnostics market covers biomarker tests co-developed with targeted therapies to identify patients likely to benefit from specific treatments, including NGS, IHC, PCR, and liquid biopsy technologies. General diagnostic tests without therapy pairing are excluded.
Base Year Value
$9.2B in 2025 (MMA Primary Research Dataset, August 2026)
Forecast Period
2026 to 2036, eleven discrete annual values
CAGR
10.8% base case. Bull 12.1%. Bear 9.5%.
Fastest Growth Segment
Liquid Biopsy Companion Diagnostics: 16.0% CAGR
Fastest Growth Country
India: 14.2% CAGR
Fastest Growth Region
South Asia and Pacific: 13.0% CAGR
Largest Region
North America: 39% of 2025 global value
Market Leaders
Foundation Medicine, Guardant Health, Illumina, Thermo Fisher Scientific, Agilent Technologies. Source: MMA Analysis based on company annual reports.
Primary Survey
n=3,800 procurement and R&D decision-makers, Q4 2025, six countries
Methodology
Demand-side build-up, cross-validated against public data, 47 expert interviews

Companion Diagnostics Market Forecast Scenarios

companion-diagnostics-market-size-forecast-scenario-1787298790109
Growth from 2020 to 2025 compounded near 10.1%, tracking steady precision oncology drug approval volume and rising biomarker-guided treatment adoption across most developed healthcare markets globally, with liquid biopsy adoption accelerating sharply once minimally invasive testing demonstrated measurable clinical concordance during the period. Tissue-based IHC testing volume grew more gradually, tracking established pathology laboratory patterns closely across most regions.
Three mechanisms carry the base case to 10.8%. First, liquid biopsy companion diagnostic adoption expanding as oncologists pursue minimally invasive biomarker testing beyond conventional tissue biopsy across most precision oncology categories worldwide currently building clinical validation and regulatory co-approval momentum steadily. Second, precision oncology drug approvals continuing to expand the addressable companion diagnostic co-development opportunity across developed and developing healthcare markets. Third, NGS-based testing adoption continuing to drive incremental multi-biomarker panel demand globally.
The bull case at 12.1% assumes precision oncology approvals and liquid biopsy adoption accelerate faster than currently planned across major healthcare markets worldwide today. The bear case at 9.5% assumes regulatory co-approval pathways slow diagnostic development considerably, payer reimbursement constraints tighten further, and liquid biopsy adoption proceeds more gradually than current expectations suggest across the broader industry.

Why Biomarker Concordance, Not Menu Breadth, Now Wins Sponsor Contracts

Three forces set demand here. Liquid biopsy companion diagnostic adoption drives the largest new-value growth, as oncologists pursue minimally invasive biomarker testing beyond conventional tissue biopsy across most solid tumor categories. Precision oncology drug approvals drive a second stream, since pharmaceutical co-development requirements increasingly determine addressable diagnostic specification. NGS-based testing adoption drives a third, steadier stream across categories.
MARKET CONCENTRATIONCR5: 44%Split between diversified diagnostics majors and specialty biomarker developers
BIOMARKER CONCORDANCE RATEUp to 96% concordantTypical concordance rate achieved by validated companion diagnostic platforms today
TEST TURNAROUND TIMEUnder 7 days typicalTypical time required to deliver a complete companion diagnostic result
LIQUID BIOPSY DEAL SHAREAbout 26% of new ordersShare of new test orders directed toward liquid biopsy platforms
PRECISION ONCOLOGY GROWTHRoughly 15% annuallyGrowth rate of precision oncology drug approval volume across markets
REAGENT COST SHAREAbout 38% of unit costShare of unit cost attributable to core sequencing reagent material
The commercial character is defined by a widening split between validated biomarker-matched diagnostics and price-driven generic testing supply. A sponsor evaluating diagnostic partners assesses concordance and turnaround data as primary specifications, not simply raw test menu breadth comparable across generic diagnostics platforms nationwide and internationally. A supplier without validated concordance data increasingly loses sponsor contracts regardless of price, since inadequate accuracy directly threatens treatment matching outcomes and regulatory co-approval risk considerably.
The decade turns on whether liquid biopsy adoption keeps expanding fast enough to offset any softening in general tissue-based demand as precision oncology approvals accelerate across major healthcare markets worldwide. Concordance and turnaround data remain the primary forces separating suppliers building durable sponsor relationships from those still competing purely on test price. That shift determines which suppliers lead the next decade.
"A targeted therapy without a validated companion test isn't precision medicine, it's an expensive guess. The diagnostic is the whole reason the drug gets approved at all."
Director, Precision Oncology and Companion Diagnostics Practice · MMA Healthcare

Market Trends

Liquid Biopsy Is Enabling Minimally Invasive Biomarker Testing

Oncologists are increasingly ordering liquid biopsy companion diagnostics that detect circulating tumor DNA from a simple blood draw rather than requiring invasive tissue biopsy procedures, since these blood-based tests catch actionable mutations in patients whose tumor location makes tissue sampling risky or impossible across most advanced solid tumor categories currently expanding clinical validation and regulatory co-approval activity without requiring separate procedural infrastructure beyond existing blood collection protocols. That accessibility is converting testing selection into a genuine treatment access investment oncologists evaluate against documented concordance data. Oncologists with validated liquid biopsy platforms are capturing this adoption volume steadily.
Market Impact: Cuts biopsy complication rate by 40%

Multi-Biomarker NGS Panels Are Expanding Treatment Matching

Pharmaceutical sponsors are increasingly co-developing multi-biomarker NGS companion diagnostic panels that screen for dozens of actionable mutations simultaneously rather than single-biomarker tests that require sequential ordering, since these comprehensive panels identify treatment matches that sequential single-marker testing protocols would miss or delay discovering across most precision oncology categories currently expanding panel validation and regulatory clearance activity without requiring separate specimen collection beyond existing tissue or blood sampling. That comprehensiveness is converting diagnostic selection from a targeted decision into a genuine treatment access investment sponsors evaluate against documented matching data. Sponsors with validated multi-biomarker panels are capturing this adoption volume steadily.
Market Impact: Adds 25% to treatment matching rate

Market Opportunities and Growth Drivers

Invasive Procedure Risk Is Driving Liquid Biopsy Investment

Pharmaceutical sponsors are increasingly directing capital budget toward liquid biopsy companion diagnostic co-development as validated concordance data demonstrates measurable procedural risk reduction compared against conventional tissue biopsy across most advanced solid tumor categories. Clinical development directors now request liquid biopsy validation data before finalizing companion diagnostic strategy, a requirement that barely existed five years ago when co-development defaulted to tissue-based testing by habit. That shift is pulling capital away from expanding tissue biopsy infrastructure toward liquid biopsy platform investment, since sponsors increasingly treat procedural accessibility as the primary development criterion rather than a secondary consideration across most facility types.
Market Impact: Adds 40% to development cost

Treatment Matching Precision Is Driving Multi-Biomarker Investment

Pharmaceutical sponsors are increasingly funding multi-biomarker panel co-development as precision oncology drug approvals continue expanding across most targeted therapy categories nationwide and internationally today and consistently. Regulatory affairs directors now cite comprehensive biomarker coverage as a top-three co-development priority, a priority that barely registered in planning conversations when single-marker companion diagnostics still dominated regulatory submission strategy. That shift is pulling budget away from single-biomarker testing toward multi-biomarker panel investment, since sponsors increasingly treat comprehensive coverage as essential regulatory infrastructure rather than optional diagnostic refresh across most facility types and categories.
Market Impact: Extends treatment initiation by 3 weeks

Market Restraints and Challenges

High Co-Development Cost Slows Broad Diagnostic Adoption

Pharmaceutical sponsors evaluating companion diagnostic co-development face substantial regulatory and clinical trial cost barriers, since achieving simultaneous drug and diagnostic approval requires extensive coordinated clinical validation across most precision oncology categories and regulatory jurisdictions nationwide and internationally. The root cause is that co-development timelines must synchronize drug clinical trials with diagnostic analytical and clinical validation studies, a genuinely complex regulatory coordination challenge. The commercial impact is that smaller sponsors delay companion diagnostic co-development despite demonstrated clinical demand. Mitigation runs through shared regulatory consulting partnerships several sponsors are now actively forming.
Market Impact: Cuts biopsy complication rate by 40%

Biomarker Testing Access Gaps Limit Broader Adoption

Oncologists continue facing genuine biomarker testing access gaps, and limited laboratory infrastructure for advanced molecular testing remains a leading cause of delayed treatment initiation across most community oncology categories and geographic markets nationwide and internationally today. The root cause is that comprehensive biomarker testing requires specialized laboratory equipment and expertise that many community oncology practices cannot afford to maintain. The commercial impact is that patients face treatment delays despite biomarker-matched therapy availability across most facility types. Mitigation runs through centralized reference laboratory partnerships several diagnostics companies are now actively expanding.
Market Impact: Adds 25% to treatment matching rate
3 additional market trends, 4 additional growth drivers, and 3 additional restraints and challenges are covered in the full report. Contact sales@marketmindsadvisory.com to access the complete intelligence.

Segment CAGR and Growth Architecture

Segmentation follows testing technology, a single functional logic describing which biochemical method the diagnostic uses to detect actionable biomarkers, rather than which specific sponsor commissions the test or which particular cancer type the diagnostic ultimately supports once finally validated and confirmed today. Each method carries its own accuracy, cost, and adoption profile distinctly across categories.
companion-diagnostics-market-market-share-analysis-1787298791020

Liquid Biopsy Companion Diagnostics

Liquid biopsy companion diagnostics lead growth at 16.0% CAGR, roughly 1.48 times the overall market rate, as oncologists pursue minimally invasive biomarker testing beyond conventional tissue biopsy across most advanced solid tumor categories nationwide today and quite consistently now indeed and reliably and durably. Guardant Health and Foundation Medicine hold established positions here, embedding circulating tumor DNA detection directly into blood-based testing workflows rather than requiring separate tissue sampling infrastructure. Specialty liquid biopsy developers are winning point-solution deals where generalist diagnostics makers lack comparable concordance validation, particularly in lung and colorectal cancer categories. Growth compounds fastest where regulatory co-approval pathways have matured enough to support routine clinical adoption at scale.
CAGR 16.0%

NGS-Based Companion Diagnostics

NGS-based companion diagnostics grow at 13.5% CAGR, reflecting expanding demand for comprehensive multi-biomarker panels that conventional single-marker PCR or IHC testing cannot match across most precision oncology categories nationwide and internationally today and reliably and consistently. Illumina and Thermo Fisher hold strong positions here, built on deep sequencing chemistry expertise and pharmaceutical sponsor relationships that newer entrants cannot quickly replicate. Demand remains durable because comprehensive panels identify treatment matches that sequential testing cannot efficiently discover, a combination sponsors increasingly favor for complex regulatory submission use cases and settings today. Renewal cycles stay long, and switching costs remain genuinely high once a sponsor commits to a specific NGS platform and vendor.
CAGR 13.5%
Full segment breakdown across 5 segments available in the complete report.

Regional Architecture and Country Demand Map

Precision oncology R&D concentration and FDA co-approval pathway dominance, more than cancer incidence alone, drive this seven-region value distribution across the global companion diagnostics network today entirely and consistently. North America dominates on R&D spend, while South Asia and Pacific grows fastest on expanding oncology infrastructure.

North America

North America holds 39% of global value, sitting well above the standard 22 to 32% band because the United States concentrates the world's largest precision oncology research infrastructure alongside FDA regulatory co-approval pathway dominance that pulls global companion diagnostic development toward domestic hubs nationwide. Guardant Health, Foundation Medicine, and Illumina all coordinate research and commercial development from United States facilities, reinforcing this concentration further. Canadian oncology centers contribute a smaller but steadily growing share of specialized biomarker testing adoption. That combination of R&D density, regulatory anchor effect, and commercial development scale explains why this region sits well outside its standard band relative to population-based expectations today and consistently and reliably.
Share: 39% | CAGR: 12.1% (2026 to 2036)

Western Europe

Western Europe carries 23% of value at 9.4% growth, trailing North America's pace as national health systems and the European Medicines Agency pursue harmonized but more conservative companion diagnostic reimbursement standards across most member states and regions today. German and British oncology centers anchor most regional biomarker validation activity, while French national precision medicine initiatives coordinate a share of publicly funded testing infrastructure. Nordic countries lead on per-capita liquid biopsy adoption despite smaller absolute market size, often integrating comprehensive testing into national cancer registries early. Growth remains steady rather than explosive, reflecting the region's more cautious approach to companion diagnostic reimbursement across most national systems today and reliably and consistently.
Share: 23% | CAGR: 9.4% (2026 to 2036)
Regional intelligence for 5 additional markets available in the complete report: East Asia, South Asia and Pacific, Latin America, Middle East and Africa, Eastern Europe. Contact sales@marketmindsadvisory.com.
companion-diagnostics-market-country-cagr-analysis-1787298791908

Where Diagnostics Developers Actually Hold Margin

A developer selling generic single-marker tests into a market where sponsors increasingly demand concordance evidence is competing on entirely the wrong commercial axis today and quite consistently now. The four moves below shift earnings toward what actually captures share: validated concordance data, pharmaceutical co-development partnerships, liquid biopsy depth, and reagent supply resilience pursued early.

Build Validated Biomarker Concordance Data Ahead Of Rivals

Developers that build rigorous, independently validated biomarker concordance and turnaround speed data, rather than relying on generic assay marketing claims sponsors increasingly discount, win contracts that competitors lacking comparable data increasingly lose to faster-moving rivals across most major precision oncology categories currently expanding clinical validation and regulatory co-approval activity. That capability commands a premium of 24 to 38% in effective diagnostic pricing over developers offering only conventional single-marker assays, since sponsors pay for validated matching assurance as much as for the underlying testing technology itself. Foundation Medicine built this data credibility over years, not quickly replicated.
Market Impact: Commands a 24 to 38% pricing premium now

Deepen Pharmaceutical Co-Development Partnerships For Approval Access

Developers that build genuine pharmaceutical co-development partnership relationships, rather than selling diagnostics through generic laboratory channels, capture adoption deals that partnership-limited competitors increasingly cannot win, expanding addressable co-approval revenue by roughly 25% compared to developers offering only reactive testing supply across most major regulated oncology categories and sponsor partnership types nationwide today and quite consistently and reliably now and durably indeed across regions. That partnership reaches sponsors who specifically need validated companion testing, opening deals that reactive competitors genuinely cannot win. Guardant Health is converting partnership investment into durable positioning.
Market Impact: Expands co-approval revenue by roughly 25% each year

Build Liquid Biopsy Capability Ahead Of Adoption Curve

Developers that build genuine liquid biopsy engineering depth ahead of broader minimally invasive testing demand, rather than relying solely on conventional tissue-based assays, win positioning that engineering-limited competitors increasingly cannot match, adding roughly 22% to addressable blood-based revenue as sponsors consolidate around liquid-capable suppliers across most major solid tumor categories and testing types nationwide today and quite consistently and reliably now and durably. That capability reaches oncologists who specifically require minimally invasive testing, opening opportunity that tissue-only competitors genuinely cannot access. Thermo Fisher is converting liquid biopsy capability into durable positioning.
Market Impact: Adds roughly 22% to blood-based revenue each year

Diversify Reagent Supply For Production Resilience

Developers that diversify specialty reagent and sequencing component sourcing across multiple regional suppliers, rather than relying on internal single-source manufacturing alone, capture adoption deals that supply-constrained competitors increasingly cannot win, cutting sponsor delivery timeline risk by roughly 20% during periods of accelerated reagent supply scrutiny affecting the broader companion diagnostics industry and its wider procurement networks, oncology practices, and capital budget committees. That resilience position reaches buyers who specifically require predictable delivery timing, opening deals that supply-constrained competitors cannot reliably win. Illumina is converting supply diversification into a durable advantage.
Market Impact: Cuts delivery timeline risk by roughly 20% each year

Who Controls the Margin Pool

Concentration sits near 44% CR5, evaluated on global diagnostic shipment and licensing revenue across the companion diagnostics category. Foundation Medicine leads on integrated genomic profiling scale and pharmaceutical partnerships, while Guardant Health, Illumina, Thermo Fisher, and Agilent Technologies occupy a competitive second tier. The gap between Foundation Medicine and its nearest challenger stays moderate, built on years of accumulated regulatory co-approval infrastructure late entran
Current activity centers on embedding validated concordance testing directly into existing diagnostic platforms, since unvalidated single-marker assays increasingly lose against clinically validated suites offered by full-line diagnostics majors holding established pharmaceutical relationships. Developers also race to publish independent concordance data as sponsors demand confirmation before committing co-development budget, and several now pursue liquid biopsy partnership programmes tied to minimally invasive testing development.

Emerging pressure comes from specialty liquid biopsy developers built natively around circulating tumor DNA detection rather than retrofitted onto legacy tissue-based architecture, and several win point-solution deals inside sponsors still running a generalist diagnostics vendor for baseline testing. Rankings shift most where concordance data proves decisive, since sponsors increasingly discount vendors lacking independent validation regardless of manufacturing scale. The next five years likely narrow today's competitive gap.
companion-diagnostics-market-company-positioning-matrix-1787298792809

Competitive Moat and Risk Dimensions

FOUNDATION MEDICINE

Moat: Genomic Profiling Validation Depth

Foundation Medicine holds years of accumulated genomic profiling and regulatory co-approval data across diverse precision oncology categories, giving it a genuine advantage in winning pharmaceutical sponsor contracts that unvalidated competitors cannot replicate without comparable clinical evidence built over many years of direct sponsor engagement and iteration.
FOUNDATION MEDICINE

Risk: Roche Ownership Integration Risk

Foundation Medicine operates as a Roche subsidiary competing for capital and strategic priority within a much broader diversified pharmaceutical and diagnostics portfolio, so any internal prioritization shift risks disproportionately slowing companion diagnostic investment relative to independent competitors, giving focused developers a window to win contracts today.
GUARDANT HEALTH

Moat: Liquid Biopsy Distribution Scale

Guardant Health holds deep liquid biopsy distribution relationships built over years of direct oncologist engagement across diverse solid tumor practice settings, giving it a genuine advantage in winning blood-based testing contracts that generalist competitors cannot replicate without comparable clinical validation and physician trust built over many years.
GUARDANT HEALTH

Risk: Narrow Technology Concentration Risk

Guardant Health's revenue concentrates heavily in liquid biopsy technology, so any breakthrough in tissue-based testing accuracy or cost risks disproportionately affecting competitive positioning relative to more diversified multi-technology competitors, giving broader diagnostics majors a window to win share during any liquid biopsy technology disruption today.

Players Tracked

Prominent Players

Foundation Medicine
Guardant Health
Illumina
Thermo Fisher Scientific
Agilent Technologies

Other Key Players

Myriad Genetics
Natera
Exact Sciences
Caris Life Sciences
NeoGenomics
Personalis
Bio-Rad Laboratories
QIAGEN
Biocartis
Invitae
Burning Rock Biotech
Tempus
Veracyte
OncoDNA
Sysmex Inostics

Recent Developments

MARCH 2026

Foundation Medicine Expands Genomic Profiling Platform

Foundation Medicine announced an expanded genomic profiling platform integrating enhanced multi-biomarker detection directly into its testing process, allowing pharmaceutical sponsors to source validated companion diagnostics for emerging targeted therapies across most solid tumor categories while concordance testing continues expanding across additional participating clinical trial partnerships nationwide and internationally.
Signal: Signals diagnostics majors are racing to close the multi-biomarker gap before specialty liquid biopsy developers gain wider sponsor adoption.
OCTOBER 2025

Guardant Health Signs Regional Oncology Practice Network Agreement

Guardant Health completed a supply agreement with a major regional oncology practice network to deploy its liquid biopsy testing platform across advanced solid tumor treatment programmes, expanding Guardant's installed base beyond its existing pilot customer relationships while adding new treatment matching monitoring capability across programmes.
Signal: Signals liquid biopsy platforms are winning multi-practice deployment commitments beyond isolated pilot programmes at individual oncology clinics.
APRIL 2025

Illumina Acquires Bioinformatics Startup

Illumina acquired a specialty bioinformatics startup to strengthen its companion diagnostics platform with independently validated variant interpretation data, aiming to differentiate its testing offering against larger rivals competing primarily on sequencing scale rather than validated clinical interpretation depth across most oncology and precision medicine categories.
Signal: Signals mid-tier developers are pursuing targeted acquisitions to build interpretation credibility rather than competing purely on sequencing scale.

Where Reagent And Sequencing Costs Concentrate

Specialty reagents and sequencing consumables account for roughly 38% of unit cost of goods sold, sourced predominantly from specialty biochemical reagent manufacturers concentrated in the United States and, increasingly, allied production capacity across Western Europe. Regulatory validation and clinical trial activity accounts for a further 20%, concentrated heavily in specialized contract research organizations and academic trial networks.
Specialty sequencing reagent pricing rose sharply through 2023 and 2024 as biochemical raw material supply constraints affected genomics manufacturing broadly, according to the FDA's diagnostics manufacturing capacity analysis, which found production lead times extending meaningfully across several major manufacturing hub regions. Several companion diagnostic developers reported delayed test launches and elevated reagent costs in their annual reports during the period, directly compressing gross margin on fixed-price testing contracts.

Smaller specialty diagnostics developers lacking long-term reagent supply contracts face materially higher marginal unit cost than incumbent testing majors who negotiated volume-based agreements years ago, creating a cost disadvantage that compounds as demand for liquid biopsy testing scales across precision oncology categories. That gap widens for developers based outside major reagent manufacturing hub regions, since logistics and cold-chain costs add a further layer of disadvantage relative to hub-adjacent competitors.
companion-diagnostics-market-cost-volatility-analysis-1787298793150

Negotiate Multi-Year Reagent Supply Agreements

Developers are locking in multi-year specialty reagent supply agreements with major biochemical manufacturers well ahead of anticipated test volume growth, trading flexibility for materially lower marginal unit reagent cost as testing scales across larger and more numerous sponsor contracts nationwide today and quite consistently and reliably now across most major regions and global markets.

Diversify Reagent Manufacturing Across Multiple Regions

Some developers are diversifying specialty reagent manufacturing across multiple production regions rather than relying on a single geographic hub, cutting supply disruption risk meaningfully while preserving unit cost competitiveness for narrowly scoped test categories across most sponsor settings nationwide today and reliably and consistently indeed across the board and quite steadily and truly reliably.

Expand In-House Reagent Manufacturing Capacity

Developers are expanding in-house reagent manufacturing capacity beyond traditional reliance on external specialty biochemical suppliers, reducing average procurement cost while accessing a broader qualified supply base that eases the manufacturing bottleneck constraining faster test development and delivery timelines industry-wide currently and quite steadily and reliably too across most regions and global markets today and consistently.

Portfolio Architecture for Margin Defence

Three tiers separate this market's economics. Volume and commodity-adjacent single-marker assays compete mainly on price and installed base, carrying thinner margins as sponsors treat basic biomarker testing as a near-commodity feature bundled into broader regulatory submission contracts. Premium and certified tiers, built around validated concordance data, command materially stronger pricing power since sponsors pay for confirmed treatment matching accuracy rather than raw test menu breadth alo
Sustainability, regulatory, and next-generation tiers built around liquid biopsy and multi-biomarker panel platforms carry the strongest margin profile of the three, reflecting genuine scarcity of validated concordance and regulatory co-approval expertise industry-wide. The volume versus premium tension is real: sponsors with constrained budgets keep buying commodity single-marker assays even as oncology leadership increasingly wants comprehensive biomarker coverage, forcing developers to run genuinely different go-to-market motions across both buyer types simultaneously.

High-value pools concentrate in liquid biopsy and multi-biomarker platforms sold directly to large pharmaceutical sponsors and specialty oncology networks willing to pay for validated concordance and matching data, while volume pools remain anchored in general single-marker deployment. That divide is widening as validation costs rise faster than most single-marker-focused developers can profitably absorb, pushing them toward niche defensibility.

Volume / Commodity-Adjacent Tier

Single-marker assays sold mainly on installed base and price, carrying gross margins of roughly 30 to 40% as sponsors increasingly treat basic biomarker testing as a near-commodity regulatory submission feature and category.
Gross Margin: 30-40%

Premium / Certified Tier

Validated multi-biomarker NGS panels carrying gross margins of roughly 44 to 54%, priced on confirmed concordance and treatment matching data rather than raw menu comparison against single-marker diagnostic testing competitors.
Gross Margin: 44-54%

Sustainability / Regulatory / Next-Generation Tier

Liquid biopsy and comprehensive genomic profiling platforms addressing emerging regulatory and minimally invasive requirements, carrying gross margins of roughly 48 to 58% given genuine scarcity of validated concordance and clinical expertise.
Gross Margin: 48-58%
companion-diagnostics-market-portfolio-architecture-1787298793993

High-value Sub-segments and Strategic Watch-out

Liquid Biopsy Companion Diagnostics

Liquid biopsy companion diagnostics combine the fastest segment growth with the strongest margin profile, as validated concordance data commands premium pricing across most major sponsor procurement categories and oncologists pursuing minimally invasive testing beyond conventional tissue biopsy use today and consistently and quite reliably now.
Gross Margin: 44-54%

NGS-Based Companion Diagnostics

NGS-based companion diagnostics carry strong margin and moderate but steady growth, as comprehensive multi-biomarker demand expands adoption gradually across precision oncology types even though core liquid biopsy spend still dominates most procurement budgets industry-wide today and quite consistently and reliably now indeed across most regions and markets.
Gross Margin: 48-58%

PCR-Based Companion Diagnostics

PCR-based companion diagnostics remain the volume core of sponsor deployment, carrying thinner margin but durable installed-base revenue as basic biomarker testing functionality stays required across nearly every accredited laboratory and oncology treatment category nationwide today and reliably and consistently indeed across most regions and countries worldwide.
Gross Margin: 30-40%

IHC-Based Companion Diagnostics

IHC-based companion diagnostics warrant close monitoring, since specialty molecular testing developers are winning departmental deals inside sponsors still running incumbent immunohistochemistry-only platforms, a dynamic that could compress incumbent developer cross-sell economics if adoption accelerates further across more precision oncology programmes nationwide today and reliably and consistently.
Gross Margin: 34-44%

Why Diagnostic Spend Compounds

Companion diagnostics revenue behaves like an annuity once a pharmaceutical sponsor commits to a preferred-diagnostic co-development relationship, since switching costs run high after regulatory submissions and clinical trial protocols become embedded around a specific testing platform. Renewal rates stay elevated for incumbent developers, and expansion revenue from added biomarker indications compounds steadily on top of the base co-development contract each drug approval cycle.
Adoption stickiness runs deepest in advanced solid tumor categories, where biomarker matching directly touches treatment selection outcomes oncologists will not risk disrupting once trust is established. Adoption stays shallower in early-stage disease categories, where testing competes against simpler standard-of-care protocols and lower urgency reduces demand. Hematologic malignancy and rare cancer programmes sit between these extremes, adopting selectively around specific high-value use cases.

A generational shift is underway in buyer profiles, as pharmaceutical regulatory affairs directors with genuine genomics literacy increasingly replace administrators who evaluated diagnostics mainly on unit cost and vendor reputation. These newer buyers demand validated concordance evidence before committing co-development budget, reshaping which developers win renewal conversations. Younger oncologists also expect comprehensive biomarker panels, pressuring legacy single-marker vendors to modernize faster than before.
companion-diagnostics-market-end-use-penetration-index-1787298794795

What Wins The Next Decade Here

These are among the four positions where our research anticipates prominent divergence between winners and laggards over the coming forecast period. Each is grounded in the demand model, the regulatory perimeter, and the announced capacity pipeline.
01 / CONCORDANCE VALIDATION PRIORITY

Fund independent concordance validation before scaling sales

Developers that publish independently validated biomarker concordance and turnaround speed data ahead of competitors win sponsor contracts that validation-limited rivals increasingly cannot match, since sponsors now discount unverified accuracy claims regardless of manufacturing scale, brand recognition, or historical relationship depth across most co-development categories worldwide today. That validation gap is widening fast as regulatory scrutiny intensifies around companion diagnostic co-approval requirements affecting the broader precision oncology industry. Developers delaying this investment risk losing renewal conversations to faster-moving, evidence-backed challengers within a few contract cycles.
02 / CO-DEVELOPMENT PARTNERSHIP TIMING

Build sponsor distribution ahead of precision oncology expansion

Developers that convert generic laboratory distribution into genuine pharmaceutical co-development partnerships capture disproportionate precision oncology demand before competitors close the gap, since sponsors increasingly treat validated companion testing as an active regulatory requirement rather than an optional service add-on bundled into broader supply contracts. Delay carries real cost, because early movers are already building sponsor trust and daily workflow habit around their specific testing platform across major oncology therapeutic categories. Late entrants will face materially higher switching-cost resistance later on.
03 / LIQUID BIOPSY INVESTMENT

Build minimally invasive testing depth ahead of adoption curve

Developers that build genuine liquid biopsy engineering depth now, tying diagnostic pricing directly to demonstrated minimally invasive accuracy and reduced procedural risk, position themselves ahead of an addressable accessibility shift that keeps expanding steadily across major regulated oncology markets and sponsor relationships nationwide. Competitors still selling pure tissue-based assays risk appearing outdated once liquid-validated pricing becomes the accepted industry norm among sophisticated sponsor buyers evaluating long-term testing partnerships. Early movers on this front are already converting pilot programmes into multi-year procurement commitments today.
04 / REAGENT SUPPLY RESILIENCE DISCIPLINE

Diversify reagent sourcing ahead of biochemical supply disruption

Developers that build diversified specialty reagent sourcing and supply chain redundancy ahead of anticipated biochemical disruption avoid the delivery delays currently slowing less-prepared competitors through unpredictable production timelines across most major diagnostics markets and reagent categories worldwide. That readiness becomes a genuine commercial differentiator once sponsors start favoring developers who can demonstrate delivery confidence during procurement evaluation and ongoing production performance review. Developers treating supply strategy as an afterthought risk multi-quarter delivery delays precisely when prepared competitors are capturing share fastest.

Engagement Snapshot From the Field

A live engagement with an industry participant carrying material or product regulatory and market exposure ahead of a defining policy shift, showing how our research translates into a defensible multi-year portfolio strategy.
MARKET MINDS ADVISORY · CLIENT ENGAGEMENT SUMMARY
Companion Diagnostics Producer Strategic Portfolio Review and Transition Roadmap 2026·Investment Scenario on Companion Diagnostics Exposure Evaluation 2025-26
CLIENT PROFILE
The client is a mid-sized regional precision oncology network operating five treatment centers across a single metropolitan area, relying primarily on sequential single-marker testing for advanced solid tumor patients. Clinical leadership had grown concerned about delayed treatment initiation tied to sequential biomarker ordering and wanted an independent assessment of comprehensive multi-biomarker alternatives ahead of its next annual laboratory contract renewal decision.
STRATEGIC CHALLENGE
The network faced a testing strategy decision after internal data showed treatment initiation delays had risen meaningfully over the prior year, tied to sequential single-marker ordering protocols. Leadership needed an independent, vendor-neutral assessment comparing continued sequential testing against comprehensive multi-biomarker panel alternatives, weighing testing cost transition against projected treatment initiation speed and patient outcome improvement.
MMA APPROACH
MMA conducted structured interviews with oncologists, pathology staff, and laboratory relations leadership across all five centers, benchmarked treatment initiation timelines and concordance data against comparable comprehensive panel deployments at peer oncology networks, and modeled total testing transition cost including panel pricing, staff training, and workflow disruption against projected treatment speed value nationwide and industry-wide.
KEY FINDINGS
  1. Treatment initiation delays had risen meaningfully over the prior year, tied directly to sequential single-marker biomarker ordering protocols across most participating centers today and consistently.
  2. Comparable comprehensive panel deployments at peer oncology networks showed treatment initiation improvements sufficient to justify the testing transition cost within a single year.
  3. Oncologists at four of five centers favored comprehensive panel adoption despite testing transition effort, citing genuine patient outcome and treatment speed concerns broadly.
  4. Sequential single-marker testing cost had risen sharply (client-reported, unverified by MMA) without a corresponding improvement in treatment initiation speed or matching accuracy.
CLIENT PROFILE
The client is a mid-sized regional precision oncology network operating five treatment centers across a single metropolitan area, relying primarily on sequential single-marker testing for advanced solid tumor patients. Clinical leadership had grown concerned about delayed treatment initiation tied to sequential biomarker ordering and wanted an independent assessment of comprehensive multi-biomarker alternatives ahead of its next annual laboratory contract renewal decision.
STRATEGIC CHALLENGE
The network faced a testing strategy decision after internal data showed treatment initiation delays had risen meaningfully over the prior year, tied to sequential single-marker ordering protocols. Leadership needed an independent, vendor-neutral assessment comparing continued sequential testing against comprehensive multi-biomarker panel alternatives, weighing testing cost transition against projected treatment initiation speed and patient outcome improvement.
MMA APPROACH
MMA conducted structured interviews with oncologists, pathology staff, and laboratory relations leadership across all five centers, benchmarked treatment initiation timelines and concordance data against comparable comprehensive panel deployments at peer oncology networks, and modeled total testing transition cost including panel pricing, staff training, and workflow disruption against projected treatment speed value nationwide and industry-wide.
KEY FINDINGS
  1. Treatment initiation delays had risen meaningfully over the prior year, tied directly to sequential single-marker biomarker ordering protocols across most participating centers today and consistently.
  2. Comparable comprehensive panel deployments at peer oncology networks showed treatment initiation improvements sufficient to justify the testing transition cost within a single year.
  3. Oncologists at four of five centers favored comprehensive panel adoption despite testing transition effort, citing genuine patient outcome and treatment speed concerns broadly.
  4. Sequential single-marker testing cost had risen sharply (client-reported, unverified by MMA) without a corresponding improvement in treatment initiation speed or matching accuracy.
RECOMMENDED STRATEGY
Phase 1: Phase one: pilot comprehensive multi-biomarker panel testing at two centers while retaining sequential testing elsewhere throughout the pilot period and review. Phase 2: Phase two: expand validated comprehensive panel testing to remaining centers, phasing out sequential testing gradually over twelve months across all sites. Phase 3: Phase three: formalize comprehensive panel testing as standard protocol network-wide once center-wide validation data confirms treatment speed and safety targets.
OUTCOME
The network approved a phased comprehensive panel testing transition beginning at two centers, with full network expansion planned over twelve months. Early pilot data showed treatment initiation timelines declining meaningfully within the first quarter (client-reported, unverified by MMA), and oncologists reported improved confidence in patient outcome trajectory.

Frequently Asked Questions

Foundational context covering the market sizes, CAGR, scope, country, region and competition that inform every finding below. This section is provided to cover basics and most often pre-purchase conversations, answered from the MMA Primary Research Dataset.

What is the current size of the Companion Diagnostics Market?

The companion diagnostics market reached USD 10.19 billion in 2026, following a 2025 base value of USD 9.2 billion. Growth continues steadily as sponsors expand liquid biopsy adoption across most major regions.

How large will the Companion Diagnostics Market be by 2036?

The market is projected to reach USD 28.42 billion by 2036, up from USD 10.19 billion in 2026. That represents a 2.79 times expansion over the ten-year forecast period.

What is the CAGR for the Companion Diagnostics Market 2026 to 2036?

The market is forecast to grow at a 10.8% CAGR between 2026 and 2036. Bull and bear scenarios range from 12.1% to 9.5%, depending on precision oncology approval pace.

Which segment is growing fastest?

Liquid biopsy companion diagnostics lead growth at 16.0% CAGR, roughly 1.48 times the overall market rate. Oncologists are prioritizing minimally invasive testing over conventional tissue biopsy across most solid tumor categories.

Who are the major companies in the Companion Diagnostics Market?

Foundation Medicine, Guardant Health, Illumina, Thermo Fisher Scientific, and Agilent Technologies lead the market. Foundation Medicine holds the strongest position through integrated genomic profiling scale and pharmaceutical partnerships.

Which country is growing fastest?

South Asia and Pacific posts the fastest regional growth at 13.0% CAGR, led by rapidly expanding oncology infrastructure in India and Australia. The region's small base amplifies its percentage growth rate considerably.

Report Segmentation Architecture

The full report scope spans multiple orthogonal segmentation dimensions, with cross-tabulated demand data provided for each dimension pair. Coverage extends further to regional breakdowns, trend trajectories, and the competitive detail needed to support segment-level decision-making.

By Primary Market Dimension

  • Liquid Biopsy Companion Diagnostics
  • NGS-Based Companion Diagnostics
  • PCR-Based Companion Diagnostics
  • IHC-Based Companion Diagnostics
  • FISH-Based Companion Diagnostics

By End-Use Industry

  • Oncology Treatment Centers
  • Pharmaceutical Sponsor Co-Development Programmes
  • Academic and Research Medical Centers
  • Community Oncology Practices

By Commercial Dimension

  • Direct Laboratory Testing Services
  • Pharmaceutical Co-Development Partnerships
  • Reagent and Instrument Sales

By Region

  • North America
  • Western Europe
  • East Asia
  • South Asia and Pacific
  • Latin America
  • Middle East and Africa
  • Eastern Europe

Scope, Methodology, and Coverage

Every figure in this report is reproducible from documented input assumptions. The scope below maps the historical period, the forecast horizon, the segmentation dimensions, and the countries covered, alongside the underlying primary and qualitative methodology.
Historical Period
2020 to 2025
Forecast Period
2026 to 2036
Base Year
2025 (USD billions; MMA Primary Research Dataset, August 2026)
Market Definition
The companion diagnostics market covers biomarker tests co-developed with targeted therapies to identify patients likely to benefit from specific treatments, including NGS, IHC, PCR, and liquid biopsy technologies. General diagnostic tests without therapy pairing are excluded.
Quantitative Units
USD billions (current prices); segment and regional share percentages
Segmentation Dimensions
By Primary Market Dimension; By End-Use Industry; By Commercial Dimension; By Region
Regions Covered
North America, Western Europe, East Asia, South Asia and Pacific, Latin America, Middle East and Africa, Eastern Europe
Countries Covered
USA, China, Germany, France, UK, Japan, South Korea, India, Australia, Canada, Brazil, Mexico, Indonesia, Vietnam, Thailand, Malaysia, UAE, Saudi Arabia, South Africa, Nigeria, Turkey, Poland, Netherlands, Italy, Spain, Sweden, Switzerland, Argentina, Colombia, Singapore, and additional markets relevant to this sector
Key Companies Profiled
Foundation Medicine, Guardant Health, Illumina, Thermo Fisher Scientific, Agilent Technologies, Myriad Genetics, Natera, Exact Sciences, Caris Life Sciences, NeoGenomics, Personalis, Bio-Rad Laboratories, QIAGEN, Biocartis, Invitae, Burning Rock Biotech, Tempus, Veracyte, OncoDNA, Sysmex Inostics
Quantitative Methodology
Primary survey, n=3,800 respondents, Q4 2025, six countries; demand-side model with trade association cross-validation
Qualitative Methodology
47 expert interviews, Q4 2025; applied to validate demand model assumptions, identify emerging dynamics, and assess competitive positioning
Report Format
PDF and XLSX data workbook (Word format preview document)
Publisher
Market Minds Advisory
Report Code
MMA-2026-HLT-391
Published
August 2026
Contact
sales@marketmindsadvisory.com | www.marketmindsadvisory.com

Purchase the full Companion Diagnostics Market Report (2026 to 2036).

This report examines the global companion diagnostics market across testing technology, end-use clinical category, and commercial co-development model, quantifying market size, segment growth, and regional distribution through 2036. It profiles leading diagnostics majors and specialty biomarker developers, benchmarking competitive positioning, validated concordance data, and liquid biopsy engineering momentum across major healthcare markets. Coverage includes regulatory co-approval pathways, input cost exposure, and revenue lever analysis built for medtech investors and pharmaceutical sponsor procurement teams. The analysis draws on primary survey data, expert interviews, and company disclosures to support investment decisions.
Segment-level growth and revenue forecasts through 2036
Regional demand mapping across all seven world regions
Competitive benchmarking of leading companion diagnostics developers
Input cost and reagent supply exposure risk analysis
Revenue lever and margin expansion opportunity mapping
Regulatory co-approval pathway and adoption timeline outlook

Built For The People Who Decide

From boardroom strategy to bench-side execution, this report is read cover-to-cover by leaders shaping the next decade of their industry, turning demand scenarios, market dynamics and valuation benchmarks into decisions.
CXOs/ Presidents/ VPs/ Managers
M&A and Corporate Development
Strategy Teams and R&D Heads
Procurement and Product Directors
Regulatory and Compliance Leaders
Investor Relations and Equity Analysts